Axsome Therapeutics Doses First Patient in FORWARD Phase 3 Trial for Fibromyalgia

Axsome Therapeutics has initiated the FORWARD Phase 3 trial for AXS-14 (esreboxetine) to treat fibromyalgia. The first patient has been dosed, marking the beginning of the trial. Patients will be randomly assigned to receive either AXS-14 or a placebo after a 12-week open-label treatment period. The primary endpoint of the trial is the time from randomization to loss of therapeutic response.